KING PHARMACEUTICALS
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $546 | $14,049 | $-7,432 | $14,477 |
Gross Profit | 6,507 | 14,049 | -7,432 | 14,477 |
EBITDA | 71,944 | -1,092 | -151,474 | -30,377 |
EBIT | 71,944 | 6,341 | -162,337 | -24,462 |
Net Income | 69,927 | -8,645 | -157,989 | -34,468 |
Net Change In Cash | 546 | 14,049 | -7,432 | 14,477 |
Free Cash Flow | 388 | -21,126 | -48,293 | -3,824 |
Cash | 18,951 | 44,268 | 4,286 | 127,788 |
Basic Shares | 4,635 | 4,956 | 4,963 | 4,986 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $5,249 | $1,330 | $58,132 | $98,721 |
Gross Profit | 1,847 | 1,330 | 58,132 | 98,721 |
EBITDA | 141 | -4,445 | -41,062 | 38,239 |
EBIT | 141 | -4,445 | -49,317 | 30,554 |
Net Income | 324 | -4,215 | -60,355 | 25,624 |
Net Change In Cash | 5,249 | 1,330 | 58,132 | 98,721 |
Free Cash Flow | -1,266 | -2,485 | -195,928 | -394,430 |
Cash | 4,286 | 5,553 | 46,624 | 66,087 |
Basic Shares | 4,995 | 7,701 | 4,355 | 4,303 |
